A Study of Multiple Doses of LY3305677 in Healthy Participants

NCT03325387 · Completed

Last updated 2026-05-28

This clinical trial tests the safety of multiple doses of the drug LY3305677 in healthy adult participants by monitoring for any serious side effects.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 56 people

Who can join Ages 20–65 · all sexes Healthy volunteers accepted.

Timeline Started 2017-10 · est. completion 2018-08

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT03325387 ↗

Description as written by the study sponsor.

The purposes of this study are to determine: * The safety of LY3305677 and any side effects that might be associated with it. * How much LY3305677 gets into the bloodstream and how long it takes the body to remove it in healthy participants, including those of Japanese origin. * The effect LY3305677 has on the body, particularly the effect on blood glucose levels. This study will last approximately 17 weeks not including screening. Screening is required within 4 weeks prior to start of the study. This study is for research purposes only and is not intended to treat any medical conditions.

Treatments tested

LY3305677 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03325387 ↗